EyePoint Pharmaceuticals Inc

+0.09 (+1.10%)
Earnings Announcements

Eyepoint Pharmaceuticals Reports Positive 30-Day Safety Results For All Cohorts From The Davio Trial Of Eyp-1901 For Wet-AMD

Published: 07/06/2021 11:22 GMT
EyePoint Pharmaceuticals Inc (EYPT) - Eyepoint Pharmaceuticals Reports Positive 30-day Safety Results for All Cohorts From the Davio Trial of Eyp-1901 for Wet-amd.
Eyepoint Pharmaceuticals Inc - All Dose Cohorts Have Reached at Least 30-day Post-dosing Follow Up.
Eyepoint Pharmaceuticals Inc - No Serious Adverse Events (saes), Ocular Or Systemic, Were Reported.
Revenue is expected to be $8.7 Million
Adjusted EPS is expected to be -$0.45

Next Quarter Revenue Guidance is expected to be $9.91 Million
Next Quarter EPS Guidance is expected to be -$0.44

More details on our Analysts Page.